Regeneron

News

SCOTUS ruling on PCSK9 could rewrite status quo on patents

On the face of it, the battle between Amgen and Sanofi/Regeneron being heard in the US Supreme Court is a mundane biopharma contest over rights and royalties on PCSK9 inhi

News

Sanofi, Regeneron’s wager on Dupixent in COPD pays off

Approval in COPD could unlock a $3 billion market opportunity for the drug, say analysts.

News

Dupixent works in hard-to-treat form of atopic dermatitis

IL-4 inhibitor shows its worth in atopic hand-foot dermatitis unresponsive to corticosteroids.

News

Regeneron is off to CHAPLE as FDA starts pozelimab review

The C5 inhibitor is vying to become the first approved drug for the ultra-rare immune disorder.

News

Trials cue up new use for Roche's eye disease drug Vabysmo

Roche is on course for a third indication for its fast-growing ophthalmic disease therapy Vabysmo, after a pair of phase 3 trials showed it was effective at improving eyes

News

ASH: CD20 bispecific antibodies take centre stage in lymphom...

As Roche heads towards an FDA verdict on its CD20xCD3 bispecific Lunsumio for lymphoma before the end of this year, rivals from Regeneron and AbbVie are starting to nip at its heels, with n

SCOTUS ruling on PCSK9 could rewrite status quo on patents

Sanofi, Regeneron’s wager on Dupixent in COPD pays off

Dupixent works in hard-to-treat form of atopic dermatitis

Regeneron is off to CHAPLE as FDA starts pozelimab review

Trials cue up new use for Roche's eye disease drug Vabysmo

ASH: CD20 bispecific antibodies take centre stage in lymphom...

CDMOs: Their crucial role and how to select one, with Sigma ...

How to meet your physicians where they are online

Regeneron

Editor's Picks